English

The foundation aims to: 

 

The foundation aims to achieve its goals by: 

DEPAR, Dutch southwest Psoriatic Arthritis Registry, is a registry set up by the organization Cicero Rheumatology, a collaboration of rheumatologists working in 11 different hospitals in the Netherlands. DEPAR, with the participation of well over 900 patients, supports rheumatologists to gain insight into the treatment and course of psoriatic arthritis. For this, all patients with psoriatic arthritis from the collaborating hospitals will be entered into the DEPAR register and followed for three years.

The research 

 

Currently, the disease can be treated. Various treatment options are available to us, but it is unclear which treatment is the best. Collaborating rheumatologists expect to reach the best treatment for psoriatic arthritis by focusing on patients in the study, and therefore improve the course of the disease.

Psoriatic arthritis: what are its course and treatment?

Psoriatic arthritis is a chronic joint inflammation that affects one or more joints. It can also cause inflammation of the attachment points of tendons and ligaments. As a result, joint damage, loss of function, and disability can be observed in PsA. Despite the lack of a specific treatment for PsA, The treatment strategies used for inflammatory arthritis in general also treat PsA. 

 

In order to find out which treatment is most effective for psoriatic arthritis, it is substantial to investigate that we need which parameters in the study and how we can convert these into useful measuring instruments. With the aid of accurate measuring tools, the course of the disease can be managed with low disease activity, minimal joint damage, and less disability. 

We are grateful to all patient and patient partners and rheumatological treatment team members for their continuing effort to collaborate to expand our knowledge of Psoriatic Arthritis. 

STAMP stands for Strategy therapies aiming at Minimal Disease Activity (MDA) in Patients with Psoriatic Arthritis (PSA). 

 

 

A scientific drug study that focuses on comparing two different types of treatment strategies in patients who have recently been diagnosed with Psoriatic Arthritis (PsA). 

 

The study compares 2 types of treatment strategies; the first is the first-line therapy currently prescribed by rheumatologists, and the second is a therapy that begins with secukinumab, an IL-17A blocker that is normally only given later in therapy. The aim is to achieve MDA as soon as possible. MDA stands for minimal disease activity. 

It is checked whether your illness has responded sufficiently to the medication by your rheumatologist every 3 months. During the visits, to determine whether you achieve MDA or not, a score is calculated by using both the physical examination and completed questionnaires by you. If MDA is reached, you continue to use the same medication, if MDA is not reached, the medication will be adjusted. The study lasts for 1 year. 

iPROLEPSIS is a HorizonEurope-funded project developing a novel personalised digital care ecosystem for people with Psoriatic Arthritis. The project is a collaboration between 15 partners from 9 countries.

The goal

The goal of iPROLEPSIS is to propose a novel ecosystem that involves Real Worl Data (RWD) collection mechanisms and a powerful decision support system to provide new knowledge for the key actionable factors that affect the health-to-PsA transition, adopting a multiscale/ multifactorial approach, so, with the use of xAI-based models, to offer an efficient, effective, and clinically validated personalised digital care ecosystem for PsA patients.

IoT sensing technologies and a mobile application will be at the heart of the RWD collection procedure, while retrospective and prospective multi-source data will be collected from the clinical partners’ databases, combined with open access ones.

Through the analysis and visualisation of these data using AI predictive models and an intuitive visual analytics tool, respectively, the iPROLEPSIS will be able to propose personalized treatments (i.e., diet, physical activity, stress/fatigue/pain management), assisting doctors, caregivers, and hospitals towards the optimal management of PsA.

Finally, through xAI techniques, iPROLEPSIS aims to facilitate hospitals and policy makers in gaining new insights towards better clinical practices, thus shaping future PsA treatment policies.

More information?
Please visit our official iPROLEPSIS website: https://www.iprolepsis.eu/

Coming Soon

PEPSA – optimizing the Patient Experience of newly diagnosed PsA patients  

For her Master's Thesis at the faculty of Industrial Design and Engineering at the TU Delft, Lise executed the PEPSA project. Here she put her efforts towards improving the patient experience of newly diagnosed PsA patients during the first year after diagnosis.  

 

During this first phase after diagnosis, patients must learn how to cope with a chronic disease that seeps through all facets of life. This has a tremendous physical and mental impact on their lives. The diagnosis of psoriatic arthritis influences the perception of their identity and how they think others perceive them. The patients want to remain valuable and independent, whereas the PsA causes them to change their daily lives and become more dependable.  

 

“Patients have the idea that the PsA sometimes takes control over their life.” 

 

In co-creation with 5 PsA patients, various design directions were explored and evaluated with various prototypes. It resulted in: The PEPSA journal. The journal contains several modules that encourage users to think about the various aspects of their life, their Psoriatic Arthritis and how they relate to one another. In this way, the PEPSA journal allows the user to get more insights into their situation and a clearer view of their life with psoriatic arthritis, putting them back in control.  

 

Would you like to know more about this project? You can find the report here:  

https://repository.tudelft.nl/islandora/object/uuid%3A77d0d4ab-f50d-4c71-9098-504228b6ef40?collection=education 

The CICERO Foundation (Collective Initiative for Creative and Educational Rheumatism Research) was founded by (internist) rheumatologists and clinical immunologists in the South-West Netherlands region. The aim of the foundation is to promote knowledge and quality of treatment for patients with rheumatic diseases and to promote cooperation in the South-West Netherlands region with regard to care, scientific research, and continuing education. CICERO organizes, among other things, reference evenings for rheumatologists, clinical immunologists, physician assistants, and scientists from the region. 

The CICERO Foundation is a partnership between rheumatologists spread over 15 hospitals in the region. Together they started a scientific study into the condition of psoriatic arthritis. They do this under the name DEPAR. This is a registry designed to better understand the course of psoriatic arthritis and improve the treatment of the disease. 

Scientific research into the condition of psoriatic arthritis has been conducted through Cicero for several years now. It does this under the name DEPAR. This is a registry designed to better understand the course of psoriatic arthritis and improve the treatment of the condition. More information about DEPAR can be found here. 

This website has been set up in the context of this research, where you as a patient can find all information about the condition and the course of the research. If you have any questions, you can always contact the hospital in question. 

 

ANBI 

CICERO has had an ANBI status since 2016. 

Scientific research: 

For a number of years now, scientific research has been conducted through Cicero into the condition of psoriatic arthritis. It does this under the name DEPAR. This is a registry designed to better understand the course of psoriatic arthritis and improve the treatment of the condition. More information about DEPAR can be found here. 

 

Information: 

This website has been set up in the context of this research, where you as a patient can find all information about the condition and the course of the research. If you have any questions, you can always contact the relevant hospital.